Podium2Screen

Its videos from each congress, the newest first.

ESMO 2026

Madrid, October 23–27, 2026

All ESMO 2026 highlights

LITESPARK-011 : Belzutifan + Lenvatinib vs Cabozantinib After IO in RCC | Dr. Daniel Heng #ESMO26
Genitourinary. Dr. Daniel Heng. Trial update.
Does Adding Nivolumab Help in MIBC? CA017-078/ ENERGIZE Explained | Andrea Necchi | ESMO 2026
Genitourinary. Dr. Andrea Necchi. Trial update.
evERA : Giredestrant + Everolimus: evERA Biomarker Analyses | Sara Tolaney | ESMO 2026
Breast. Dr. Sara Tolaney. Trial update.
VOLGA Phase 3 Trial: Durvalumab + Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC
Genitourinary. Dr. Tom Powles. Trial update.
NEW for ESMO26: Podium2Screen Dr. Alexander Drilon from Memorial Sloan Kettering Cancer Center
Lung and thoracic. Trial update.

The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.

Email address

Your role

Your country

How we use your details

Podium2Screen

ESMO 2026

LITESPARK-011 : Belzutifan + Lenvatinib vs Cabozantinib After IO in RCC | Dr. Daniel Heng #ESMO26

Does Adding Nivolumab Help in MIBC? CA017-078/ ENERGIZE Explained | Andrea Necchi | ESMO 2026

evERA : Giredestrant + Everolimus: evERA Biomarker Analyses | Sara Tolaney | ESMO 2026

VOLGA Phase 3 Trial: Durvalumab + Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC

NEW for ESMO26: Podium2Screen Dr. Alexander Drilon from Memorial Sloan Kettering Cancer Center

The week in oncology, in your inbox